polypid announces last patient in for planned unblinded interim analysis in the ongoing shield ii phase 3 trial evaluating d-plex₁₀₀ for the prevention of abdominal colorectal surgical site infections
Unblinded Interim Analysis to be Conducted During the Current Quarter Top-line Results Anticipated in First Quarter of 2025 PETACH TIKVA,...